GTCbio, Philadelphia, PA
October 4-5, 2007
A great deal of knowledge is unraveling complex molecular and cellular changes associated with malignant tumor progression. With this come opportunities for therapeutic development. Featuring the latest tools, models, and research findings the 4th Tumor Progression & Therapeutic Resistance conference on October 4-5, 2007 in Philadelphia, PA is a great opportunity to learn and develop new approaches and collaborations. We invite members of both academia and industry to attend the meeting and participate in the discussions.George D. Yancopoulos, M.D., Ph.D., Executive Vice President at Regeneron Pharmaceuticals will deliver the Keynote address at this year`s conference. Sessions for the 4th TPTR conference include: • Signaling Pathways and Therapeutic Resistance
• Cancer Genetics & Genomics
• Tumor-Stromal Interactions & Tumor Microenvironment
• Cancer Stem Cells
• Mechanisms of Metastasis
• Molecular Diagnostics in Cancer The program also includes less formal poster sessions, and social and networking events. To present a poster, please submit an abstract August 4, 2007. A few abstracts will be selected for oral presentations.
|
|
|
Invited Speakers:
|
|
[KEYNOTE] George D. Yancopoulos, M.D., Ph.D.
Executive Vice President, CSO, Regeneron Pharmaceuticals [FEATURED] Catherine A. Wheeler, Ph.D.
Therapeutic Expert for Medical Science - Oncology, Roche
Ryan J. Watts, Ph.D.
Tumor Biology and Angiogenesis, Genentech, Inc.
Beverly A. Teicher, Ph.D.
Vice President, Oncology Research, Genzyme Corp. Elizabeth Buck, Ph.D.
Department of Translational Research, OSI Pharmaceuticals, Inc. Frank Boschelli
Department of Oncology, Wyeth Research
Anil Bagri
Tumor Biology and Angiogenesis, Genentech, Inc. Jeffrey A. Ecsedy, Ph.D.
Department of Oncology, Millennium Pharmaceuticals, Inc. Antonio Giordano
Sbarro Institute for Cancer Research and Molecular Medicine, Temple University Sharoni Jacobs
Affymetrix, Inc. David A. Tice, Ph.D.
Department of Cancer Biology, MedImmune, Inc. Bart Lutterbach
Cancer Biology and Therapeutics, Department of Molecular Oncology, Merck & Co.
Janine Arts, Ph.D.
Johnson & Johnson Pharmaceutical Research & Development, Oncology
Brian Keith, Ph.D.
Director of Education, Abramson Cancer Research Inst., University of Pennsylvania Jeffrey R. Jackson. Ph.D.
Director of Biology, Oncology Center of Excellence in Drug Discovery, GlaxoSmithKline Chang Bai
Dept of Human Genetics, Merck & Co. James Hardwick, Ph.D.
Oncology Molecular Profiling, Merck & Co. Jacek Capala, Ph.D.
Radiation Biology, NCI/NIH
Rosie Kaplan, M.D.
Assistant Clinical Member, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College
Richard Pestell, M.D., Ph.D.
Director, The Kimmel Cancer Center, VP, Oncology Services, Thomas Jefferson University Hospital
Vice President, Oncology Services,
Nicholas J Gaspar
Scios, Inc. Stephen Tahir, Ph.D.
Research Investigator, Oncology, Abbott Laboratories
|
|